Related Experiment Video
Updated: Jun 18, 2026
09:30
The Synthesis of RGD-functionalized Hydrogels as a Tool for Therapeutic Applications
Published on: October 7, 2016
11.3K
DNA-Based Hydrogels with Multidrug Sequential Release for Promoting Diabetic Wound Regeneration.
Wei Li1, Hui Xie2, Liping Gou1
1Department of Endocrinology and Metabolism, Center for Diabetes and Metabolism Research, West China Hospital, Sichuan University, Chengdu 610041, China.
JACS Au
|September 29, 2023
Summary
This study introduces Agilegel, a novel DNA-based hydrogel designed for diabetic wound healing. Agilegel precisely releases antibacterial, antioxidant, anti-inflammatory, and angiogenic agents sequentially to accelerate wound closure.
Area of Science:
- Biomaterials Science
- Regenerative Medicine
- Wound Healing
Background:
- Diabetic wounds (DW) present complex healing challenges including infection, oxidative stress, inflammation, and poor angiogenesis.
- Effective DW management necessitates sequential delivery of bactericidal, antioxidative, anti-inflammatory, and angiogenic agents.
Purpose of the Study:
- To develop a DNA-based multidrug hydrogel (Agilegel) for controlled, sequential release of therapeutic agents to promote diabetic wound regeneration.
Main Methods:
- Agilegel was engineered with a hierarchical structure to achieve sequential release of vascular endothelial growth factor-alpha (VEGF-α), silver nanoclusters (AgNCs), and interleukin-10 (IL-10).
- Release mechanisms involved covalent bonds, noncovalent bonds, and physical encapsulation within the DNA hydrogel structure.
Main Results:
- Agilegel demonstrated effective bacterial elimination via AgNCs and ROS mitigation via DNA scaffolds.
- IL-10 promoted M1 to M2 macrophage polarization, reducing inflammation.
- VEGF-α stimulated cell proliferation, angiogenesis, and extracellular matrix formation, accelerating DW closure.
Conclusions:
- DNA hydrogels offer a versatile platform for precisely regulating sequential drug release.
- Agilegel shows significant potential for phased, multi-agent intervention in complex disease treatment, particularly for diabetic wound healing.
